×

Sign In

Search
Home

Intellia Therapeutics’ rare genetic disorder therapy meets main goal in trial

By Thomson Reuters Apr 27, 2026 | 6:06 AM

April 27 (Reuters) – Intellia ‌Therapeutics said ‌on Monday ⁠its ⁠experimental therapy for a ⁠rare ⁠genetic disorder has met ‌the ⁠main goal in ⁠a ‌late-stage ⁠study.

(Reporting by ‌Kunal Das; Editing ⁠by Vijay Kishore)

Space analytics firm HawkEye targets $2.4 billion valuation in US IPO

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Verizon lifts annual profit forecast after surprise rise in wireless subscribers

US refiners' first-quarter profits expected to jump as war lifts fuel margins

Romania's largest party teams up with far-right opposition to topple pro-European coalition

Pope and first female Archbishop of Canterbury meet and pray together

Privacy Policy
Terms Of Service

Copyright © 2026. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.